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Abstract 
In addition to maternal genes and environmental exposures, variation in fetal imprinted genes 
could also affect maternal blood pressure during pregnancy. Our objective was to test the 
associations between polymorphic variants in 16 imprinted genes and maternal mean arterial 
blood pressures in 1,160 DNA trios from two established birth cohorts (the Cambridge Baby 
Growth and Wellbeing Studies), and seek replication in 1,367 Hyperglycemia and Adverse 
Pregnancy Outcome Study participants. Significant univariate associations, all independent of 
fetal sex, were observed in the Cambridge cohorts, including: FAM99A rs1489945 
transmitted from the mother (p=2x10-4), DLK1 rs10139403 (mother; p=9x10-4), DLK1 
rs12147008 (mother; p=1x10-3), H19 rs217222 (father; p=1x10-3), SNRPN rs1453556 (father; 
p=1x10-3), IGF2 rs6356 (father; p=1x10-3) and NNAT rs6066671 (father; p=1x10-3). In meta-
analysis including additional independent Hyperglycemia and Adverse Pregnancy Outcome 
Study data, the association with maternally-transmitted fetal DLK1 rs10139403 reached 
genome-wide significance (p=6.3x10-10). With the exception of fetal rs1489945 and 
rs217222, all of other associations were unidirectional and most were statistically significant. 
To further explore the significance of these relationships we developed an allele score based 
on the univariate findings. The score was strongly associated with maternal blood pressure at 
31 weeks (p=4.1x10-8; adjusted r2=5.6%) and 37 weeks of pregnancy (p=1.1x10-4; r2=3.6%), 
and during the last 2 weeks prior to parturition (p=1.1x10-10; r2=8.7%). It was also associated 
with gestational hypertension (odds ratio 1.54 (1.14, 2.09) per allele; p=0.005; 45 cases and 
549 controls). These data support the concept that fetal imprinted genes are related to the 
development of gestational hypertension. 
 
Key words: pregnancy-induced hypertension, preeclampsia, gestational hypertension, 
placenta, meta-analysis 
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Introduction 
Epidemiological studies such as the Swedish Twin Register and Medical Birth Register 
suggest that pregnancy-induced hypertension (raised blood pressure which originates in 
pregnancy and encompasses both gestational hypertension and preeclampsia) has both 
genetic and environmental aetiological components1. Genetic variation may have a key role 
in the overall control of blood pressure in pregnant women, but the maternal genetic variants 
linked or associated with gestational hypertension, preeclampsia or changes in blood 
pressure2 only account for a small fraction of the total genetic risk of pregnancy-induced 
hypertension3. The reasons for this may relate to a the lack of sensitivity of even large 
genome wide association studies (GWAS) to detect associations with small effect sizes, 
effects of rare variants with large effect sizes, and gene-gene and gene-environmental 
interactions4, like those observed for non-gravid hypertension5. 
 
An additional explanation, only pertinent to pregnancy, is that some of the genetic risk could 
relate to the fetal rather than maternal genotype. It has been suggested that fetal genes may 
influence maternal metabolism and physiology6 and we hypothesised that fetal growth genes 
in particular, may influence a mother’s risk of developing gestational hypertension and 
gestational diabetes7,8. Consistent with this, in the Swedish Birth and Multi-Generation 
Registries 20% of the variability in the risk for preeclampsia could be attributed to fetal 
genetic effects9. Of fetal growth genes, imprinted genes, with their role in regulating fetal 
growth10 and their parent of origin-specific effects, are thought to mediate part of the 
“separate evolutionary reproductive needs” of the father and the mother11. Paternally-
expressed imprinted genes tend to enhance fetal growth whereas maternally-expressed genes 
tend to restrain it. It has been suggested that the mechanism behind these processes arise from 
changes in fetal demand and supply12. Consistent with the hypothesis, in pregnancies affected 
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by Beckwith Wiedemann syndrome, a fetal overgrowth syndrome caused by deletion or 
mutation of fetal imprinted genes within the 11p15 chromosomal region, the mother is at 
increased risk of developing gestational hypertension and preeclampsia13. 
 
In this study we explored this hypothesis further by investigating associations between 
polymorphic variation in fetal imprinted genes and maternal blood pressure in pregnancy. 
 
Methods 
Cohort 1: Cambridge Baby Growth Study 
The prospective and longitudinal Cambridge Baby Growth Study recruited mothers (and their 
partners and offspring) attending ultrasound clinics during early pregnancy at the Rosie 
Maternity Hospital, Cambridge, U.K. between 2001-200914. Study participant characteristics 
are shown in Table 1A. Of the 2,229 mothers initially recruited to the study, all routinely 
performed blood pressure measurements in the pregnancy that were recorded in the hospital 
notes were collected retrospectively. In total, 845 DNA trios were collected from the families 
of the mothers. Blood and/or mouth swab samples for DNA extraction were collected from 
the father and the offspring after birth. In this cohort 96.9% of the offspring were of 
Caucasian ethnicity, 0.8% were of mixed race, 0.6% were Black (African or Caribbean), 
0.8% were East-Asian and 0.9% were Indo-Asian. 
 
Cohort 2: Cambridge Wellbeing Study 
The Cambridge Wellbeing Study is a retrospective study that recruited mothers, fathers and 
children where the pregnant mother had delivered a full term, singleton baby at the Rosie 
Maternity Hospital between 1999-200014. Exclusion criteria were maternal chronic 
hypertension and treatment for diabetes during pregnancy. Study participant characteristics 
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are shown in Table 1B. In this cohort all the offspring were of Caucasian ethnicity. We 
sought permission from the mother's General Practitioner to approach the mother, partner and 
child to collect their DNA samples by postal mouth swab kits. In total 315 DNA trios were 
collected out of 563 women who consented. 
 
Cohort 3: Hyperglycemia and Adverse Pregnancy Outcome Study 
To validate our seven most significant findings in the Cambridge cohorts we tested the same 
associations between maternal mean arterial blood pressures and the fetal imprinted gene 
alleles in 1,367 HAPO study participants15, 16 of European descent whose single nucleotide 
polymorphism (SNP) genotypes were derived from a GWAS of maternal glycemic and 
neonatal anthropometric traits17. Study participant characteristics are shown in Table 1C. In 
these women blood pressure was measured between 24 and 32 weeks of gestation (as close to 
28 weeks as possible) using standardised procedures and a calibrated electronic device 
(Omron 711, Illinois, U.S.A.)18. 
 
Ethical Approval 
The Cambridge Baby Growth and Wellbeing Studies were approved by the local ethics 
committee, Addenbrooke’s Hospital, Cambridge, U.K. In the HAPO Study the protocol was 
approved by each field centre’s local institutional review board. All procedures followed 
were in accordance with institutional guidelines. Written informed consent was obtained from 
the parents in each of the cohorts studied, including consent for inclusion of their infants.  
 
Blood Pressure Categorisation in the Cambridge Cohorts 
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Routine blood pressure measurements during pregnancy were extracted from hospital notes 
and categorised into one of four time-points: around 12, 31, 37 and 37~41 weeks of 
pregnancy. Further details are presented in the Online Supplement. 
 
Gene Selection and Genetics 
Genomic DNA from the Cambridge Baby Growth Study blood samples was extracted using 
an Autopure LS Machine (Qiagen Ltd., Crawley, U.K.). Other genomic DNA, from the 
Cambridge Baby Growth and Wellbeing Studies, was extracted from mouthswab samples 
using a standard chloroform-based method. The genes that were studied ((Table S1) DLK1, 
FAM99A, GNAS, GRB10, H19, IGF2, INS, KCNQ1OT1, MEST, NNAT, PEG3, PEG10, 
PLAGL1, SGCE, SNRPN, ZIM2) were chosen because they were all imprinted (and 
paternally-expressed with the exception of H19 whose function includes regulating 
expression of paternally-expressed IGF2) and are placentally-expressed at some stage of 
development19. The 155 SNP variants in these 16 genes were haplotype tag SNPs covering 
the gene and 20kb either side of it, identified by Tagger (r2 > 0.8 and minor allele frequency > 
0.2) from the Centre d’Etude du Polymorphisme Humain population (Utah residents with 
ancestry from Northern and Western Europe) of HapMap Project Build 36 using 
Haploview20. The one exception to this was IGF2 where 11 of the tagging SNPs were 
previously identified21. A complete list of the SNPs that were genotyped are listed in Table 
S1. The DNA samples were genotyped using proprietary Kompetitive Allele Specific PCR 
assays, which are SNP genotyping assays using Fluorescence Resonance Energy Transfer 
quencher cassette oligonucleotides (designed and performed by LGC Genomics, Hoddesdon, 
U.K.). In HAPO the DNA samples were genotyped using the Illumina Human 610 Quad v1 B 
SNP array (Illumina Inc., San Diego, U.S.A.) and additional SNPs were imputed17. The SNP 
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genotypes that were used in this study were consistent with Hardy Weinberg equilibrium (p > 
0.05 using the χ2 test) and had a repeat genotyping discordancy rate of < 1.0%. 
 
Statistical Analyses and Composite Score Formulation 
A detailed description of the statistical analyses performed, including the formulation of the 
composite fetal imprinted gene allele score, the linear regression models used to test 
associations between maternal mean arterial blood pressures and either individual fetal 
imprinted gene variants or the allele score, and a power calculation are presented in the 
Online Supplement. The effects of multiple testing were minimised by considering only the 
associations between the allelic score and four blood pressure readings primary (all other 
associations being viewed as secondary). A p-value < 0.0125 was therefore considered 
statistically significant. Effect sizes are presented as Cohen’s d (where there are two groups 
being compared) or adjusted r2 values (where there are more than two groups being 
compared). Unless otherwise stated all other data are presented as means (95% confidence 
intervals). Statistical analyses were performed using either Stata 13 (StataCorp LP, College 
Station, Texas, U.S.A.) or R version 3.2.2 (http://cran.r-project.org/bin/windows/base/). 
 
Results 
Associations with Maternal Mean Arterial Blood Pressures in the Cambridge Baby Growth 
and Wellbeing Studies 
Table 2 shows the seven strongest associations between fetal imprinted gene SNP alleles and 
maternal mean arterial blood pressures in univariate linear regression models (the remainder 
of the statistically significant associations being shown in Table S3). Although two of the 
SNPs tagged polymorphic variation in DLK1 they were not in linkage disequilibrium in our 
Cambridge Baby Growth and Wellbeing Studies (r2=0.49, D’=0.89). None of these strongest 
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associations also showed an interaction with fetal sex, although some of the other fetal 
imprinted gene SNP alleles showed sex-specific associations with maternal blood pressure 
(Table S4). None of the other p-values, from statistical models involving associations 
between the 155 fetal SNPs (2 parental transmissions per SNP) and 4 blood pressure readings 
per subject, crossed the significance threshold.  
 
Confirmation of Univariate Analyses in HAPO and Meta-analysis 
Table 3 shows the univariate associations between the seven fetal SNP alleles whose 
associations with maternal blood pressures in the Cambridge Baby Growth and Wellbeing 
Studies had the lowest p-values and maternal mean arterial blood pressures around week 28 
of pregnancy in HAPO participants. None of these associations reached statistical 
significance, although, apart from the associations with maternally-transmitted fetal FAM99A 
rs1489945 and paternally-transmitted fetal rs217222, all the associations were in the same 
direction as those from the Cambridge Studies. In the meta-analysis that included data from 
the analysis of the Cambridge Studies one of the associations with maternal mean arterial 
blood pressure reached genome-wide statistical significance (maternally-transmitted fetal 
DLK1 rs10139403, p=6.3x10-10). Others associations were also significant (paternally-
transmitted fetal IGF2 rs6356, p=6.0x10-6; paternally-transmitted fetal NNAT rs6066671, 
p=0.006) or borderline significant (maternally-transmitted fetal DLK1 rs12147008, p=0.04; 
paternally-transmitted fetal SNRPN rs1453556, p=0.02). Only two of the seven fetal SNP 
alleles showed no sign of any significant association (maternally-transmitted fetal FAM99A 
rs1489945, p=0.27; paternally-transmitted fetal H19 rs217222, p=0.31). 
 
Development of the Composite Fetal Imprinted Gene Allele Score 
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The effect size for the association between any of the maternal mean arterial blood pressure 
measurements and the developmental composite fetal imprinted gene allele scores were 
maximised when the composite score was formulated based on the 7 fetal SNP alleles with 
the lowest p-values in the univariate analyses: FAM99A rs1489945 transmitted from its 
mother, DLK1 rs10139403 (mother), DLK1 rs12147008 (mother), H19 rs217222 (father), 
SNRPN rs1453556 (father), IGF2 rs6356 (father) and NNAT rs6066671 (father). Table 5 
shows the associations between the composite fetal imprinted gene allele score and maternal 
mean arterial blood pressures at different stages of pregnancy. There was no significant 
association with maternal blood pressures at 12 weeks gestation, but all the readings in the 
second half of pregnancy were significantly associated with the composite fetal imprinted 
gene allele score. Fig. 1 shows the composite fetal imprinted gene allele scores plotted 
against the mean arterial blood pressures at week 12 of pregnancy and in the last two weeks 
of pregnancy. 
 
Associations with Maternal Gestational Hypertension in the Cambridge Baby Growth and 
Wellbeing Studies 
The composite fetal imprinted gene allele score was significantly associated with the 
development of gestational hypertension in the Cambridge Baby Growth and Wellbeing 
Studies (odds ratio 1.54 (1.14, 2.09) per allele; p = 0.005; 45 cases and 549 controls). 
 
Discussion 
This study has shown novel fetal genetic variants that are robustly associated with maternal 
blood pressure in the second half of pregnancy in a non sex-specific manner. This adds to 
previous reports of genetic associations found between autosomal fetal but not maternal 
variants and gestational hypertension in small, unreplicated studies22,23 and variable 
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associations between maternal blood pressure and interactions between fetal sex and maternal 
variants24-26. Our results are consistent with the suggestion that the fetal genome is able to 
influence maternal blood pressure in pregnancy7,8, although they are associations rather than 
demonstrating causality. When the alleles from these variants were amalgamated as a 
composite score there were significant associations demonstrated with each of three maternal 
blood pressure readings taken across the second half of pregnancy in our Cambridge cohorts. 
 
Interestingly there were only weak associations with the maternal blood pressure reading 
taken in the first trimester of pregnancy. Any hypertension detected at that stage of pregnancy 
would be considered by definition chronic hypertension rather than gestational hypertension. 
Fetal genes cannot contribute to chronic hypertension per se in pregnancy (as opposed to 
gestational hypertension superimposed upon chronic hypertension) since their effects would 
not be present outside of pregnancy. Therefore the finding that the composite fetal imprinted 
gene allele score was associated with the readings in the second half of pregnancy but not 
with that in the first is not unexpected. The association between the gene score and 
gestational hypertension itself is consistent with this. It may be that the genetic regulation of 
maternal blood pressure is dynamic throughout pregnancy as the effects of fetal genes slowly 
increase27, since our regression coefficients increase as pregnancy progresses. As a major role 
of imprinted genes is in fetoplacental growth and development10,19, it may also not be 
surprising that the effect sizes increase when fetal growth is maximal. Indeed our largest 
effect size came just prior to delivery, when fetal growth is likely to have just peaked28. At 
this stage 8.7% of the variance in the maternal blood pressure could be explained by 
associations with the score, consistent with the Swedish Birth and Multi-Generation 
Registries where 20% of the variability in liability of proteinuric gestational hypertension 
(preeclampsia) could be attributed to fetal genetic effects9. More of the variance in maternal 
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blood pressure might be attributable to additional, as yet untested fetal variants or sex-
specific associations24. 
 
The list of fetal variants with the strongest non sex-specific associations with maternal blood 
pressure were from a range of imprinted genes and different parental transmissions (other 
associations were present in a sex-specific manner suggesting different causal mechanisms). 
Consistent with imprinting effects, these associations were all parental-transmission-
dependent. The parental transmission with the significant association was not always as 
would be expected (e.g. maternally-transmitted DLK1 variants and a paternally-transmitted 
H19 variant). However the variants with the significant associations were genotyped as tags 
rather than potential functional variants and no assertions of causality can be made. Their loci 
tend to be in clusters of imprinted genes, some of which are maternally-expressed and some 
paternally. Taking fetal DLK1 rs10139403 as an example, its association with maternal blood 
pressure is with the maternally-transmitted allele despite DLK1 being paternally-expressed. 
However this SNP appears to be an expression quantitative trait locus (eQTL) for 
neighbouring MEG3 which is imprinted and maternally-expressed29. 
 
Most of the associations with variants that were included in the composite fetal imprinted 
gene allele score showed some degree of replication in the meta-analysis that included results 
from HAPO, even if it were only of borderline significance for some of them. Differences 
between the HAPO Study populations and the Cambridge populations are suggested by the 
different direction of the association between maternally-transmitted fetal FAM99A 
rs1489945 and maternal mean arterial blood pressures in the three cohorts. Its link with 
maternal blood pressure in pregnancy is biologically plausible as it appears to be an eQTL for 
BRSK226 whose placental expression is raised 8.6 fold in severe preeclampsia30. The other 
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association of note in the meta-analysis is that between maternally-expressed fetal DLK1 
rs10139403 and maternal blood pressure since it reached genome wide significance. This is 
the first association between a fetal SNP allele and maternal blood pressure in pregnancy that 
crosses this threshold, with its implied validity across populations. As stated above this SNP, 
positioned in intron 1 of DLK1, appears to be a stronger eQTL for MEG3 than DLK129, a 
gene whose reduced placental expression is linked to preeclampsia and for whom in vitro 
data suggest a potential role in uterine spiral artery remodelling failure due to the aberrant 
conditioning of placental trophoblast cells31. Reduced placental MEG3 expression is also 
associated with intrauterine growth restriction32, another feature of preeclampsia. The other 
SNP tagging the DLK1 region that contributed to the composite fetal imprinted gene allele 
score in our study, rs12147008, probably relates to being a strong eQTL for Genbank 
ascension number AL117190.6, which is located in a putative intergenic differentially-
methylated region which may regulate both DLK1 and MEG3 expression33. Of the other fetal 
SNPs used in the composite score rs6356 appears to be an eQTL for TH29, itself associated 
with blood pressure variability34. Fetal SNRPN rs1453556 could affect SNRPN expression 
through altering a transcription factor binding site35, a defect in which can cause Prader Willi 
syndrome36 which itself is associated with hypertension. Fetal rs217222 is a tag for genetic 
variation in the H19 gene region, where alterations in placental imprinting have been 
implicated in the development of preeclampsia37. Fetal rs6066671 is a tag for rs6066727 
which is also predicted to alter a transcription factor binding site35 and for NNAT whose 
placental expression is raised 2.3 fold in severe preeclampsia30. All the SNPs used to 
construct the fetal imprinted gene allele score therefore have plausible links with gestational 
hypertension. 
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Although the associations between maternal blood pressures in the second half of pregnancy 
and the composite fetal imprinted gene allele score appear to be strong the study does have 
limitations including the fact that the composite score associations were only tested in the 
Cambridge cohorts and therefore could be less evident in other populations. Some of the 
limitations such as the relatively modest size of the Cambridge cohorts and the lack of 
paternity testing have been addressed previously14. Of the remaining limitations one is that 
none of the strongest associations in the Cambridge cohorts could be replicated independently 
in HAPO (just indirectly by meta-analysis). This could be for a number of possible reasons 
including: (1) the only recorded blood pressure measurement in HAPO was at a stage of 
pregnancy slightly earlier than when the strongest associations were found in the Cambridge 
cohorts and the Cambridge data suggest that generally these fetal associations are more 
evident as pregnancy progresses, (2) the exclusion of women with explicit diabetes from 
HAPO may have resulted in a depletion of hypertension risk genes given the link between 
what would previously have been considered gestational diabetes and gestational 
hypertension38, and (3) in some studies related to hyperglycemia such as HAPO there is a 
requirement for hyperglycemia to be present for certain genetic associations to become 
evident39. Another limitation is that the analysis used to construct the composite fetal 
imprinted gene allele score could be considered post hoc in nature although we constructed it 
this way due to the lack of fully established fetal imprinted gene allele associations with 
maternal blood pressures in pregnancy. A further limitation is that in our meta-analysis 
converting standardised β-coefficients into r-values sometimes had to use values which were 
outside the validated range of coefficients (-0.5 < β < 0.5, too few values being outside this 
range in Peterson and Browne’s original study to validate them)40. Since this only applied to 
rs1489945 and rs12147008, one of which was not significant and the other of which was only 
of borderline significance in the meta-analysis, it did not appear to influence the major 
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associations observed. A final limitation is that our study has only shown associations with 
tag SNPs and therefore causality cannot be inferred. 
 
Perspectives 
This study has shown novel genetic associations between fetal imprinted gene variant alleles 
and maternal blood pressures in the second half of pregnancy, the time point over which 
gestational hypertension may emerge. One of these, maternally-transmitted fetal DLK1 
rs10139403 reached genome-wide significance in the meta-analysis of its association with 
maternal blood pressure. An unweighted composite fetal imprinted gene allele score, 
constructed from the variants showing the strongest associations, was robustly associated 
with maternal blood pressures across the second half of pregnancy and with gestational 
hypertension in our Cambridge cohorts. These data support the concept that polymorphic 
variation in certain fetal genes are related to the development of gestational hypertension. 
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Novelty and Significance 
What is new We have shown, for the first time, a group of fetal imprinted gene variants that 
are robustly associated with maternal blood pressure in pregnancy. The association with one 
of them, DLK1 rs10139403, reached genome-wide significance.  
What is relevant A composite fetal imprinted gene allele score was strongly associated with 
both maternal blood pressure across the second half of pregnancy (explaining up to 8.7% of 
the variance in maternal mean arterial blood pressure), and gestational hypertension.  
Summary This study implies a potential role for fetal imprinted genes in the development of 
gestational hypertension. 
  
Petry et al., page - 21 -  HYPE201608261R2 
 
Figure Legend 
Figure 1 Scatter diagram showing the association between the composite fetal imprinted 
gene allele score and the mean arterial blood pressure (A) around week 12 of pregnancy and 
(B) in the final two weeks of pregnancy. The regression lines with their shaded 95% 
confidence intervals are shown.  
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Table 1 Study participant demographics for the (A) 845 family trios in the Cambridge Baby 
Growth Study, (B) 315 family trios in the Cambridge Wellbeing Study and (C) 1,367 
mother/baby dyads from HAPO17.  Data are mean (SD) or percentages. OGTT = oral glucose 
tolerance test. 
(A) 
Maternal Age at Delivery (years) 33.5 (4.3) 
Maternal Height (cm) 165.9 (7.2) 
Maternal Pre-pregnancy Weight (kg) 66.3 (13.5) 
Maternal Pre-pregnancy Body Mass Index (kg/m2) 24.1 (4.6) 
Pre-pregnancy Gravidity 1.8 (0.9) 
Pre-pregnancy Parity 0.4 (0.8) 
Twin Pregnancies (%) 2.0 
Maternal Smoking in Pregnancy (%) 5.4 
Gestational Age at Delivery (weeks) 39.8 (1.6) 
Offspring Ethnicity (% Caucasian) 96.9 
Offspring Sex (% male) 51.6 
Offspring Birth Weight (g) 3479 (533) 
Paternal Age at Delivery (years) 35.4 (5.3) 
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(B) 
Maternal Age at Delivery (years) 33.1 (4.1) 
Pre-pregnancy Parity 0.8 (0.8) 
Twin Pregnancies (%) 0 (inclusion criteria) 
Gestational Age at Delivery (weeks) 39.6 (1.3) 
Offspring Ethnicity (% Caucasian) 100 (inclusion criteria) 
Offspring Sex (% male) 50.8 
Offspring Birth Weight (g) 3562 (495) 
 
(C) 
Maternal Age at OGTT (years) 31.3 (5.2) 
Body Mass Index at OGTT (kg/m2) 28.5 (4.8) 
Primiparous births (%) 86.3 
Twin Pregnancies (%) 0 (inclusion criteria) 
Maternal smoking during pregnancy (%) 13.5 
Gestational Age at Delivery (weeks) 39.6 (1.1) 
Offspring Ethnicity (% Caucasian) 100 (inclusion criteria) 
Offspring Sex (% male) 49.9 
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Table 2 The seven strongest associations between fetal imprinted gene SNP alleles and maternal mean arterial blood pressures in linear 
regression models that were adjusted for gestational age of the fetus, in the Cambridge Baby Growth and Wellbeing Studies. These fetal variants 
were used in the construction of the composite fetal imprinted gene allele score. Also shown are the p-values of the associations of maternal 
mean arterial blood pressures with the equivalent maternal genotypes. The blood pressure readings labelled as being taken at 37~41 weeks were 
taken in the last two weeks prior to parturition for each pregnancy, the mean (95% confidence interval) of which occurred at 39.3 (39.3, 39.4) 
weeks.  
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Petry et al., page - 27 -  HYPE201608261R2 
 
(n=72) (n=326) 








1x10-3 0.43 0.10 0.05 0.5 0.1 








1x10-3 0.35 0.31 0.3 0.3 0.8 
IGF2, 
INS 








1x10-3 0.33 0.74 0.2 0.6 0.9 








1x10-3 0.22 0.76 0.7 0.4 0.3 
Data shown are mean (95 % confidence intervals). Effect size is Cohen’s d. 
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Table 3 Univariate association between the seven fetal SNP alleles used in the composite fetal imprinted gene allele score and maternal mean 
arterial blood pressures at 28 weeks gestation in HAPO Study participants with European ancestry.     
 






n Standardised  
β-Coefficient 




FAM99A rs1489945  Genotyped maternal C 999 -0.99 
 
0.50 0.046 
DLK1 rs10139403 Genotyped maternal G 1,067 0.11 0.60 0.860 
DLK1 rs12147008 Genotyped maternal T 1,099 0.52 0.81 0.520 
H19 rs217222 Imputed paternal G 1,149 -0.14 0.62 0.823 
SNRPN rs1453556 Genotyped paternal G 1,016 0.01 0.53 0.988 
IGF2, 
INS 
rs6356 Genotyped paternal A 1,020 0.21 0.50 0.679 
NNAT rs6066671 Genotyped paternal A 986 0.25 0.50 0.613 
  
Petry et al., page - 29 -  HYPE201608261R2 
 
Table 4 Results of the meta-analysis of the associations between maternal mean arterial blood pressures and fetal imprinted gene SNP alleles 
that were used in the composite score in the Cambridge Baby Growth Study, the Cambridge Wellbeing Study and HAPO Study participants with 
European ancestry. 






rs1489945 maternal CBGS 277 0.102 -0.498 0.271 
Wellbeing 61 0.345 
HAPO 999 -0.970 
DLK1 rs10139403 maternal CBGS 301 0.191 0.161 6.277x10-10 
Wellbeing 47 0.017 
HAPO 1,067 0.158 
DLK1 rs12147008 maternal CBGS 306 0.228 0.299 0.044 
Wellbeing 65 0.017 
HAPO 1,099 0.560 
H19 rs217222 paternal CBGS 325 0.114 0.056 0.314 
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Wellbeing 65 0.251 
HAPO 1,149 -0.137 
SNRPN 
 
rs1453556 paternal CBGS 300 0.216 0.121 0.024 
Wellbeing 64 0.079 
HAPO 1,016 0.060 
IGF2, INS rs6356 paternal CBGS 387 0.139 0.214 5.965x10-6 
Wellbeing 51 0.263 
HAPO 1,020 0.259 
NNAT rs6066671 paternal CBGS 395 0.103 0.199 0.006 
Wellbeing 60 0.171 
HAPO 986 0.295 
CBGS = Cambridge Baby Growth Study, Wellbeing = Cambridge Wellbeing Study, HAPO = Hyperglycemia and Adverse Pregnancy Outcome 
Study. For the HAPO study the r-values were estimated from the standardised β-values using the method of Peterson & Brown23. 
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Table 5 The associations between the composite fetal imprinted gene allele score and maternal blood pressure at different stages of pregnancy in 
the Cambridge Baby Growth and Wellbeing Studies. 
Stage of Pregnancy  
(Gestational Age (weeks)) 




p-value Effect Size  
(adjusted r2 (%)) 
12 577 80.6 (80.1, 81.2) 0.2 0.5 0 
31 582 81.3 (80.8, 81.9) 0.6 4.1x10-8 5.6 
37 570 85.0 (84.4, 85.6) 1.4 1.1x10-4 3.6 
37~41 457 87.5 (86.7, 88.4) 2.7 1.1x10-10 8.7 
 Data are mean (95% confidence interval). 
